Retinoids: Fascinating up-and-coming scenario

Journal of Dermatology

Volumn 30, Issue 5, 2003, Pages 355-380

  Sardana, Kabir ^a   Sehgal, Virendra N ^b,c  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

^b Sehgal Nursing Home   (India)

^c A/6 Panchwati ^*  (India)

Author keywords

Adapalene; Isotretinoin; Newer retinoids; Retinoid receptors; Retinoids; Rexinoids; Tazarotene; Tretinoin

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; 4 [2 METHYL 1 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; 7 (3,5 DI TERT BUTYLPHENYL) 3 METHYL 2,4,6 OCTATRIENOIC ACID; ADAPALENE; ALITRETINOIN; BEXAROTENE; CD 2325; CD 2396; ETRETIN; ETRETINATE; FENRETINIDE; ISOTRETINOIN; LGD 1550; POLYPRENOIC ACID; RETINAL; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOL; RETINOL PALMITATE; RO 26 4453; RO 41 5253; SR 11238; SR 11327; TAZAROTENE; TEMAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ACNE VULGARIS; ACTINIC KERATOSIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALOPECIA; ANIMAL MODEL; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; BASAL CELL NEVUS SYNDROME; BLEPHARITIS; BONE DISEASE; BRAIN PSEUDOTUMOR; CANCER CHEMOTHERAPY; CARDIOVASCULAR MALFORMATION; CATARACT; CENTRAL NERVOUS SYSTEM MALFORMATION; CHEILITIS; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA OPACITY; CORNEA ULCER; CRANIOFACIAL MALFORMATION; CREAM; DEPRESSION; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG SOLUTION; DRY EYE; DRY NOSE; EAR MALFORMATION; EPISTAXIS; ERYTHEMA; EYE IRRITATION; EYE MALFORMATION; EYE TOXICITY; FATIGUE; FOLLICULITIS; GASTROINTESTINAL TOXICITY; GEL; HEADACHE; HISTIOCYTOSIS X; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERHISTAMINEMIA; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; ICHTHYOSIS; IRRITABILITY; KAPOSI SARCOMA; KERATITIS; KERATOACANTHOMA; LETHARGY; LEUKOPLAKIA; LIMB DEFECT; LIVER CIRRHOSIS; LIVER TOXICITY; LOTION; MELANOMA; MOOD DISORDER; MOUSE; MUSCLE STIFFNESS; MYALGIA; MYOPIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NIGHT BLINDNESS; NONHUMAN; OSSIFYING MYOSITIS; OSTEOPOROSIS; PAPILLEDEMA; PERIOSTEAL THICKENING; PHASE 2 CLINICAL TRIAL; PHOTOTOXICITY; PITYRIASIS RUBRA PILARIS; PREMATURE EPIPHYSEAL CLOSURE; PROMYELOCYTIC LEUKEMIA; PSORIASIS; PSYCHOSIS; RASH; REFRACTION ERROR; RETINOIC ACID SYNDROME; RETINOL DEFICIENCY; REVIEW; SCLEROMYXEDEMA; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN LYMPHOMA; SKIN TOXICITY; SUICIDE; T CELL LYMPHOMA; TERATOGENICITY; THYMUS DISEASE; TOXIC HEPATITIS; TREATMENT INDICATION; VISUAL IMPAIRMENT; XERODERMA PIGMENTOSUM; XEROPHTHALMIA; XEROSIS;

EID: 0037832623     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2003.tb00402.x     Document Type: Review

References (86)

1. Chandraratna RA: Current research and future developments in retinoids: Oral and topical agents, Cutis, 61: 40-45, 1998.
2. Anonymous: The evolving role of retinoids in the management of cutaneous conditions, New York, USA. May 2-4, (1997), Conference proceedings, J Am Acad Dermatol, 39: s1-s122, 1998.
3. Kligman AM: The growing importance of retinoids in clinical dermatology: A retrospective and prospective analysis, J Am Acad Dermatol, 39: s1-s7, 1998.
4. Barua AB, Furr HC: Properties of retinoids. Structure, handling, and preparation, Methods Mol Biol, 89: 3-28, 1998.
5. Chandraratna RA: Future trends: A new generation of retinoids, J Am Acad Dermatol, 39: s149-s152, 1998
6. Evans TR, Kaye SB: Retinoids: Present role and future potential, Br J Cancer, 80: 1-8, 1999.
7. Zouboulis CC: Retinoids-Which dermatological indications will benefit in the near future?, Skin Pharmacol Appl Skin Physiol, 14: 303-315, 2001.
8. Johnson A, Chandraratna RA: Novel retinoids with receptor selectivity and functional selectivity, Br J Dermatol, 140: 12-17, 1999.
9. Lefebvre B, Mouchon A, Formstecher P, Lefebvre P: Distinct modes of interaction of the retinoic acid receptor alpha with natural and synthetic retinoids, Mol Cell Endocrinol, 139: 161-169, 1998.
10. Nagpal S, Chandraratna RA: Recent developments in receptor-selective retinoids, Curr Pharm Des, 6: 919-931, 2000.
11. Griffiths CE: Retinoids and vitamin D analogues: Action on nuclear transcription, Hosp Med, 59: 12-16, 1998.
12. Roos T: 'Retinoids '97': The meeting of the European retinoid research group (ERRG) (1997), Skin Pharmacol Appl Skin Physiol, 11: 166-169, 1998.
13. Orfans CE, Zouboulis CC, Roesler BA, Geilin CC: Current use and future potential role of retinoids in dermatology, Drugs, 53: 358-388, 1997.
14. Semba RD: The role of vitamin A and related retinoids in immune function, Nutr Rev, 56: s38-s48, 1998.
15. Ortanos CE, Zouboulis CC: Oral retinoids in the treatment of seborrhoea and acne, Dermatology, 196:140-147, 1998.
16. Staels B: Regulation of lipid and lipoprotein metabolism by retinoids, J Am Acad Dermatol, 45: s158-s167, 2001.
17. Geiger JM, Saurat JH: Acitretin and etretinate. How and when they should by used, Derm Clinics, 11:117-129, 1993.
18. Wiegand UW, Chou RC: Pharmacokinetics of acitretin and etretinate, J Am Acad Dermatol, 39: s25-s32, 1998.
19. Mc Connel CF: Retinoid therapy for cutaneous disease: current concepts, Curt Prob Dermatol, 12: 246-248, 2000.
20. Crabb DW, Pinairs J, Hasanadka R, et al: Alcohol and retinoids, Alcohol Clin Exp Res, 25: 207s-217s, 2001.
21. Orfanos CE: Treatment of psoriasis with retinoids: Present status, Cutis, 64: 347-353, 1999.
22. Saurat JH: Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment, J Am Acad Dermatol, 41: s2-s6, 1999.
23. Lippman SM, Lotan R: Advances in the development of retinoids as chemo-preventive agents, J Nutr, 130: 479s-482s, 2000.
24. Hansen LA, Sigman CC, Andreola F, et al: Retiholds in chemoprevention and differentiation therapy, Carcinogenesis, 21: 1271-1279, 2000.
25. Meffert H, Sonnichese n: Acitretin in the treatment of severe psoriasis: A randomized double control study comparing acitretin and etretinate, Acta Der Venereol (Stockh), 146: 176-177, 1989.
26. Torma H: Interaction of isotretinoin with endogenous retinoids, J Am Acad Dermatol, 45: s143-s149, 2001.
27. Wiegand UW, Chou RC: Pharmacokinetics of oral isotretinoin, J Am Acad Dermatol, 39: s8-s16, 1998.
28. King K, Jones DH, Daltrey DC, Cunliffe WJ: A double blind study of the effects of 13-cisretinoic acid on acne, sebum excretion rate, and microbial population, Br J Dermatol, 107: 583-590, 1982.
29. Jick H: Retinoids and teratogenicity, J Am Acad Dermatol, 39: s118-s122
30. Petkovich PM: Retinoic acid metabolism, J Am Acad Dermatol, 45: s136-s142, 2001.
31. Leyden JJ: The role of isotretinoin in the treatment of acne: personal observations, J Am Acad Dermatol, 39: s54-s49, 1998.
32. Cunliffe WJ, Caputo R, Cavicchini S: Roaccutane treatment guidelines: Results of an international study, Dermatology, 194: 351-357, 1997.
33. Goulden V, Clark SM, McGeown C, Cunliffe WJ: Treatment of acne with intermittent isotretinoin, Br J Dermatol, 137: 106-108, 1997.
34. Palmer RA, Sidhu S, Goodwin PG: Microdose isotretinoin, Br J Dermatol, 143: 205-206, 2000.
35. Ellis CN, Krach KJ: Uses and complications of isotretinoin therapy, J. Am Acad Dermatol, 45: s150-s157, 2001.
36. McLane, J: Analysis of common side effects of isotretinoin, J Am Acad Dermatol, 45: s188-s194, 2001.
37. Yob EH, Pochi PE: Side effects and long-term toxicity of synthetic retinoids, Arch Dermatol, 123: 137:5-8, 1987.
38. Gold JA, Shupack JL, Nemec MA: Ocular side effects of the retinoids, Int J Dermatol, 28: 218-225, 1989.
39. Nigra TP, Katz RA, Jorgensen H: Elevation of serum triglyceride levels from oral 13-cis-retinoic acid, in: Orfanos CE, Braun-Falco O, Farber EM, (eds): Retinoids. Advances in Basic Research and Therapy, Springer-Verlag, Berlin, 1981, pp 363-369.
40. DiGiovanna: Isotretinoin effects on bone, J Am Acad Dermatol, 45: s176-s182, 2001.
41. Ellis CN, Pennes DR, Madison KC, et al: Skeletal radiographic changes during retinoid therapy, in Saurat JH (ed): Retinoids: New Trends in Research and Therapy, Basel Karger, 1985, pp 440-444.
42. Jacobs DG, Deutsch NL, Brewer M: Suicide, depression, and isotretinoin: Is there a causal link? J Am Acad Dermatol, 45: s168-s175, 2001.
43. Chen DT: Human pregnancy experience with the retinoids, in Saurat JH (ed): Retinoids: New Trends in Research and Therapy, Basel, Karger, 1985, pp 398-406.
44. Töröck L, Kása M: Spermatological and endocrinological examinations connected with isotretinoin treatment, in Saurat JH (ed): Retinoids: New Trends in Research and Therapy, Basel, Karger, 1985, pp 407-410.
45. Bigby M, Stern RS: Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System, J Am Acad Dermatol, 18: 543-552, 1988.
46. Altman RS, Altman LJ, Altman JS: A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris, Dermatology, 204: 232-235, 2002.
47. Harms M, Pechere M, Krischer J, et al: Oral isotretinoin in HIV-positive women with acne: report of three cases, Dermatology, 196: 163-164, 1998.
48. Arechalde A, Saurat JH: Retinoids: unapproved uses or indications, Clin Dermatol, 18: 63-76, 2000.
49. Strauss JS, Leyden JJ, Lucky AW, et al: A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne, J Am Acad Dermatol, 45: 187-195, 2001.
50. Strauss JS, Leyden JJ, Lucky AW, et al: Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin, J Am Acad Dermatol, 45: 196-207, 2001.
51. Plewig G, Kligman AM: Tretinoin (all-transretinoic acid, Vitamin A Acid), in Kligman AM (ed): Acne and Rosacea, 2nd ed, Springer Verlag, Belin, 1993, pp 584-588.
52. Shapiro SS, Latriano L: Pharmacokinetic and pharmacodynamic considerations of retinoids: tretinoin, J Am Acad Dermatol, 39: s13-s16, 1998.
53. Verschoore M, Bouclier M, Czernielewski J, Hensby C:Topical Retinoids, Their uses in dermatology, Dermatol Clinics, 11: 107-115, 1993.
54. Bershad S, Poulin YP, Berson DS, et al: Topical retinoids in the treatment of acne vulgaris, Curls, 64:8-20, 1999.
55. Gendler EC: A practical approach to the use of retinoids in aging skin, J Am Acad Dermatol, 39: s114-s117, 1998.
56. Odom R: Managing actinic keratoses with retinoids, J Am Acad Dermatol, 39: s74-s78, 1998.
57. Elson ML: The role of retinoids in wound healing, J Am Acad Dermatol, 39: s79-s81, 1998.
58. Bergfeld WF: Retinoids and hair growth, J Am Acad Dermatol, 39: s86-s89, 1998.
59. Halder RM: The role of retinoids in the management of cutaneous conditions in blacks, J Am Acad Dermatol, 39: s98-s103, 1998.
60. Griffiths CE: Assessment of topical retinoids for the treatment of Far-East Asian skin, J Am Acad Dermatol, 39: s104-s107, 1998.
61. Wolf JE: An update of recent clinical trial examining adapalene and acne, J Eur Acad Dermatol Venereol, 15: 23-29, 2001.
62. Rolland A, Wagner N, Chatelus A, et al: Site-specific drug delivery to pilosebaceous structures using polymeric microspheres, Pharm Res, 10: 1738-1744, 1993.
63. Tu P, Li G-Q, Zhu X-J, et al: A comparison of adapalene gel 0.1% vs tretinoin gel 0.025% in the treatment of acne vulagaris in China, J Eur Acad Dermatol Venereol, 15: 31-36, 2001.
64. Czernielewski J, Michel S, Bouclier M, et al: Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne, J Eur Acad Dermatol Venereol, 15: 5-12, 2001.
65. Alirezai M, Meynadier J, Jablonska S, et al: Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne, Ann Dermatol Venereol, 123: 165-170, 1996.
66. Verschoore M, Langner A, Wolska H, et al: Efflcacy and safety of CD271 alcoholic gels in the topical treatment of acne-vulgaris, Br J Dermatol, 124:368-371, 1991.
67. Cunliffe WJ, Caputo R, Dreno B, et al: Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials, J Am Acad Dermatol, 36: s126-s134, 1997.
68. Shalita A, Weiss JS, Chalker DK, et al: A comparison of the efficacy and safety of adapalene gel 0.1 percent and tretinoin gel 0.025 percent in the treatment of acne vulgaris: a multicenter trial, J Am Acad Dermatol, 34: 482-485, 1996.
69. Cunliffe Wj, Poncet M, Loesche C, Verschoore M: A comparison of the efficacy and tolerability of adapalene 0.1 percent gel versus tretinoin 0.025 percent gel in patients with acne vulgaris: A meta-analysis of five randomized trials, Br J Dermatol, 139: 48-56, 1998.
70. Grosshans E, Marks R, Mascaro JM, et al: Evaluation of clinical efficacy and safety of adapalene 0.1 percent gel versus tretinoin 0.025 percent gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life, Br J Dermatol, 139: 26-33, 1998.
71. Ellis CN, Millikan LE, Smith EB, et al: Comparison of adapalene 0.1 percent solution and tretinoin 0.025 percent gel in the topical treatment of acne vulgaris, Br J Dermatol, 139: 41-47, 1998.
72. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR: Comparative tolerance of adapalene 0.1 percent gel and six different tretinoin formulations, Br J Dermatol, 139: 34-40, 1998.
73. Nyirady J, Grossman RM, Nighland M, et al: A comparative trial of two retinoids commonly used in the treatment of acne vulgaris, J Dermatol Treatment, 12: 149-157, 2001.
74. Marks R: The role of tazarotene in the treatment of psoriasis, Br J Dermatol, 140: 24-28, 1999.
75. Gollnick H, Schramm M: Topical drug treatment in acne, Dermatologg, 196: 119-125, 1998.
76. Ormerod AD: What is new in topical therapy?, Br J Dermatol, 145: 691-695, 2001.
77. Vahlquist A: What are natural retinoids?, Dermatology, 199: 3-11, 1999.
78. Anonymous: New Concepts for topical Use of Natural Retinoids: Retinaldehyde in Perspective, Proceedings of a satellite symposium of the 7th EADV meeting, Nice, France, October 7, 1998. Dermatology, 199: 1-63, 1999.
79. Ramos-e-Silva M, Hexsel DM, Rutowitsch MS, Zechmeister M: Hydroxy acids and retinoids in cosmetics, Clin Dermatol, 19: 460-466, 2001.
80. Burg G, Dummer R: Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL), Clin Lymphoma, 1: s41-s44, 2000.
81. Kerr PE, DiGiovanna JJ: From vitamin to Vesanoid: systemic retinoids for the new millennium, Med Health RI, 84: 228-231, 2001.
82. Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD-1069 on mammary carcinoma after tamoxifen failure, J Natl Cancer Inst, 15: 91: 2118, 1999.
83. Benoit GR, Flexor M, Besancon F, et al: Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells, Mol Endocrinol, 15: 1154-1169, 2001.
84. Gorgun G, Foss F: Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox, Blood, 100: 1399-1403, 2002.
85. Emilsson V, O'Dowd J, Wang S, et al: The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat, Metabolism, 49: 1610-1615, 2000.
86. Claudel T, Leibowitz MD, Fievet C, et al: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor, Proc Natl Acad Sci USA 27; 98: 2610-2615, 2001.